Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences industry that specializes in radiopharmaceuticals, today announced that it will showcase its new Actinium-225 production facility during this year’s annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting being held June 11-14 in Vancouver, British Columbia, Canada.
News | Radiopharmaceuticals and Tracers
SpectronRx to Showcase New Facility for the Global Supply of Actinium-225 at SNMMI 2022

June 13, 2022 — SpectronRx, a leading contract development and manufacturing organization (CDMO) for the life sciences ...

Time June 13, 2022
arrow
Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

June 8, 2022 — NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and ...

Time June 08, 2022
arrow
The global nuclear medicine market size is expected to reach $24.4 billion by 2030, expanding at a CAGR of 13.0% from 2022 to 2030.
Feature | Nuclear Imaging
Global Nuclear Medicine Market Analysis Report

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
Oral presentation based on Late-breaking Abstract featured at American Urological Association’s 2022 Annual Meeting (AUA2022)
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
A schematic of the 99Mo/99mTc production system based on an electron linear accelerator and activated carbon-based 99mTc generator
News | Radiopharmaceuticals and Tracers
New Production Method Promises to End Medical Radioisotope Shortages

April 22, 2022 — A commonly used radioisotope, technetium-99m, used in medical diagnoses regularly suffers from ...

Time April 22, 2022
arrow
The MARIA research reactor (Poland) has added additional operating days, which has helped to reduce the loss of HFR production capacity.
News | Nuclear Imaging
Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal

February 18, 2022 — The Nuclear Medicine Europe (NMEu) Emergency Response Team held a call on February 14 on the ...

Time February 18, 2022
arrow
MURR staff work to produce lutetium-177 (Lu-177). Image courtesy of the University of Missouri
News | Nuclear Imaging
University of Missouri Research Reactor Helps Supply Critical Medical Isotopes During Global Disruption

February 11, 2022 — Due to a recent unexpected reactor shutdown in Europe, the University of Missouri Research Reactor ...

Time February 11, 2022
arrow
Videos | Radiopharmaceuticals and Tracers
VIDEO: Advances in Radiopharmaceutical Therapy

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Supports Timely Consideration and Passage of the FIND Act of 2021 by U.S. Congress

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 17, 2021
arrow
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

September 10, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 10, 2021
arrow
GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.
News | Nuclear Imaging
GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

Time June 22, 2021
arrow
Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67)

June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time June 22, 2021
arrow
Sponsored Content | Blog | Contrast Media Injectors
BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

Time April 29, 2021
arrow
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress

April 16, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time April 16, 2021
arrow
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status
News | Radiopharmaceuticals and Tracers
Shine Medical Announces its Isotope Production Facility is Weathertight

March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of-a ...

Time March 26, 2021
arrow
Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world
News | Nuclear Imaging
IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) and NorthStar Medical Radioisotopes, LLC, announced a ...

Time March 08, 2021
arrow
NMP to evaluate technology to create new class of PET radiopharmaceuticals
News | PET Imaging
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

Time January 29, 2021
arrow
Potassium Molybdate Mo 99 Source Vessels for RadioGenix System
News | Radiopharmaceuticals and Tracers
FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes

February 18, 2020 — NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of ...

Time February 18, 2020
arrow
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s
News | Nuclear Imaging
Feinstein Institutes Develop New PET Tracer to Diagnose Parkinson’s Disease

December 26, 2019 — The Feinstein Institutes for Medical Research has received U.S. Food and Drug Administration (FDA) ...

Time December 26, 2019
arrow
Prostate cancer MRI
News | Clinical Trials
Theragnostics Reports Positive Clinical Trial Results from Prostate Cancer Study

November 15, 2019 — Theragnostics, which is developing innovative radiopharmaceuticals to improve cancer diagnosis and ...

Time November 15, 2019
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now